Appraisal of clinical practice guidelines and consensus statements on aspirin in pregnancy: a systematic review using the AGREE II instrument
Abstract
ObjectiveRecommendations regarding the use of aspirin in obstetrics vary across clinical practice guidelines and consensus statements of differing quality. This study aimed to systematically evaluate the quality of these documents, with particular focus on the recommended daily dosage, timing of initiation, and cessation of aspirin in the obstetric setting. This study employed a systematic review and quality appraisal approach using the Appraisal of Guidelines for Research and Evaluation (AGREE) II methodology.MethodsThe study included the most recent versions of all international and national/regional clinical practice guidelines and consensus statements on aspirin use in pregnancy, published in English or Chinese. Data were retrieved from PubMed (11 April 2025), three Chinese academic databases (the Chinese Medical Association Database, Wanfang Data and China National Knowledge Infrastructure) and four guideline databases (11 April 2025). Two reviewers independently screened the searched items and extracted data. Four reviewers independently scored documents using AGREE II. Recommendations from all documents were tabulated and visualized using a color-coded grid.ResultsA total of 32 documents were include, encompassing six obstetric conditions: Antiphospholipid Syndrome (APS), Fetal Growth Restriction (FGR), advanced maternal age, pregnancy loss, stillbirth and hypertension/pre-eclampsia. The included documents demonstrated strong performance in the domains of scope and purpose (median score: 89.67%, inter-quartile range [IQR] 61.11%–98.61%) and clarity of presentation (median 87.93%, IQR 50%–100%). The editorial independence domain also received relatively high score (median 73.59%, IQR 0%–100%). However, performance was lower in the domain of applicability (median 45.08%, IQR 0%–89.58%). Although aspirin 75–100 mg daily represents the most commonly recommended dosage, a broad range of dosing recommendations exists across most clinical scenarios. However, considerable controversy existed regarding the optimal timing of discontinuation, particularly in cases of hypertensive disorders of pregnancy/pre-eclampsia.ConclusionGuidelines and consensus statements, which were generally of relatively high quality, demonstrated that most documents support the use of aspirin for specific obstetric complications. Given these substantial variations in dosage ranges, treatment timing, and combination therapy recommendations, developing standardized, evidence-based protocols is essential to improve the consistency and quality of aspirin therapy in obstetric care.Systematic Review Registrationhttps://inplasy.com/inplasy-2025-4-0017, identifier INPLASY202540017.
Related
- Global perspectives on dietary management of small intestinal bacterial overgrowth (SIBO): a systematic review of clinical guidelines, consensus statements and expert recommendations
- A quality appraisal of clinical practice guidelines for herpes zoster and postherpetic neuralgia using the AGREE II instrument: A systematic review.
- Methodological quality and clinical applicability of long COVID guidelines and scientific statements: a systematic review using AGREE II and AGREE-REX
- Quality Appraisal of Clinical Practice Guidelines in Psychosocial Oncology Using the AGREE‐II Instrument
- The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustments
BibTeX
@article{hu2026appraisal,
title = {{Appraisal of clinical practice guidelines and consensus statements on aspirin in pregnancy: a systematic review using the AGREE II instrument}},
author = {Yajiao Hu and Dongxu Chen and Juan Ni and Xulin Zhang and Sainan Duan and Chao Yu},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1924311},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1924311},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Appraisal of clinical practice guidelines and consensus statements on aspirin in pregnancy: a systematic review using the AGREE II instrument
AU - Yajiao Hu
AU - Dongxu Chen
AU - Juan Ni
AU - Xulin Zhang
AU - Sainan Duan
AU - Chao Yu
PY - 2026
DA - 2026/10/30
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1924311
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1924311
AB - ObjectiveRecommendations regarding the use of aspirin in obstetrics vary across clinical practice guidelines and consensus statements of differing quality. This study aimed to systematically evaluate the quality of these documents, with particular focus on the recommended daily dosage, timing of initiation, and cessation of aspirin in the obstetric setting. This study employed a systematic review and quality appraisal approach using the Appraisal of Guidelines for Research and Evaluation (AGREE) II methodology.MethodsThe study included the most recent versions of all international and national/regional clinical practice guidelines and consensus statements on aspirin use in pregnancy, published in English or Chinese. Data were retrieved from PubMed (11 April 2025), three Chinese academic databases (the Chinese Medical Association Database, Wanfang Data and China National Knowledge Infrastructure) and four guideline databases (11 April 2025). Two reviewers independently screened the searched items and extracted data. Four reviewers independently scored documents using AGREE II. Recommendations from all documents were tabulated and visualized using a color-coded grid.ResultsA total of 32 documents were include, encompassing six obstetric conditions: Antiphospholipid Syndrome (APS), Fetal Growth Restriction (FGR), advanced maternal age, pregnancy loss, stillbirth and hypertension/pre-eclampsia. The included documents demonstrated strong performance in the domains of scope and purpose (median score: 89.67%, inter-quartile range [IQR] 61.11%–98.61%) and clarity of presentation (median 87.93%, IQR 50%–100%). The editorial independence domain also received relatively high score (median 73.59%, IQR 0%–100%). However, performance was lower in the domain of applicability (median 45.08%, IQR 0%–89.58%). Although aspirin 75–100 mg daily represents the most commonly recommended dosage, a broad range of dosing recommendations exists across most clinical scenarios. However, considerable controversy existed regarding the optimal timing of discontinuation, particularly in cases of hypertensive disorders of pregnancy/pre-eclampsia.ConclusionGuidelines and consensus statements, which were generally of relatively high quality, demonstrated that most documents support the use of aspirin for specific obstetric complications. Given these substantial variations in dosage ranges, treatment timing, and combination therapy recommendations, developing standardized, evidence-based protocols is essential to improve the consistency and quality of aspirin therapy in obstetric care.Systematic Review Registrationhttps://inplasy.com/inplasy-2025-4-0017, identifier INPLASY202540017.
SN - 1663-9812
ER -